Eyenuk Inc.’s AI-Based Diabetic Retinopathy Screening Software EyeArt™ Tested with Portable Smartphone-Based Imaging Device in New Study Indicating Potential for Highly Sensitive Yet Cost-Effective Mass Retinal Screening
Eyenuk, Inc., a leading developer of advanced clinically supported artificial intelligence (AI) enabled solutions to identify diseases via retinal image analysis, today announced the publication of a study using Eyenuk’s EyeArt™ screening software on retinal images acquired with the Remidio Fundus on Phone (FOP) system, an FDA 510k registered fundus camera which combines a smartphone with patented optics. The study demonstrated very high sensitivity for detecting both any diabetic retinopathy (DR) and sight-threatening diabetic retinopathy (STDR), indicating potential for enabling highly sensitive yet cost-effective mass retinal screening.
The research, conducted at Madras Diabetes Research Foundation (MDRF) in Chennai, India, was published in the international ‘Eye’ journal (Springer Nature) by Dr. R. Rajalakshmi and her colleagues from MDRF. The study investigators chose Eyenuk’s EyeArt™ AI screening software to analyze retinal images of individuals with diabetes taken with a Remidio Fundus on Phone system. The EyeArt™ screening software results were compared to independent blinded grading by retinal specialists to evaluate the diagnostic efficacy. Sensitivity for detecting any DR and STDR was 95.8% and 99.1% respectively, while specificity was 80.2% and 80.4% respectively. The study authors noted that some non-DR retinal lesions like drusen, RPE atrophic patch, a retinal telangiectatic vessel at macula, RPE hypertrophy, tessellated fundus and retinal vein occlusion were the causes of false positives.
“We are very encouraged by this study demonstrating impressive sensitivity and specificity using EyeArt™ with images from this novel smartphone-based fundus imaging system. This is especially notable given that our AI system was never trained on images captured by the Remidio FOP system, suggesting the robustness and broad applicability of our software algorithms,” stated Kaushal Solanki, Founder & CEO of Eyenuk, Inc. “We look forward to converting these impressive results into real-world clinical practice by eventually making EyeArt™ available for mass diabetic retinopathy screening in conjunction with a lower-cost portable high-quality fundus imaging device like the Remidio system.”
According to the World Health Organization (WHO), there are nearly 285 million visually impaired people worldwide. As many as 80% of those cases could have been avoided with early detection. With 90% of those affected living in low-income areas, an effective, accessible, affordable, and easy-to-use screening system is critical for early detection of eye diseases such as diabetic retinopathy, which if untreated may lead to blindness. Combining EyeArt™ automated AI-based screening software with an affordable camera, such as the one offered by Remidio, may provide greater and less expensive access to eye screening around the world, and potentially reduce the incidence of blindness caused by diabetic retinopathy.
Until recently, diabetic retinopathy could only be detected by trained ophthalmologists and retina specialists who examine the back of the eye (retina) or by retinal color photography taken using expensive retinal cameras. Moreover, these retinal photographs had to be interpreted by trained eye doctors. Recently, advanced technologies like Remidio FOP that combine smartphones with sophisticated optics, have enabled cost-effective and high-quality retinal imaging that was not previously possible with basic smartphone attachments. Artificial intelligence, a simulation of intelligence by a software/machine, is a specialized field based on teaching the machine, via numerous examples, to accurately interpret the images. With recent advances in AI, pioneering tools like EyeArt™ can now be used to grade retinal images of people with diabetes to determine which patients have any retinopathy, or have sight-threatening retinopathy requiring urgent referral to an ophthalmologist.
Dr. V. Mohan, Chairman, Dr. Mohan’s Diabetes Specialities Centre and Director, MDRF said, “One out of 5 Indians with diabetes are at risk for developing diabetic retinopathy. Given the alarming increase in the number of people with diabetes and shortage of trained retinal specialists, computer-based analysis using artificial intelligence of the retinal photographs, taken using sleek and user-friendly smartphone-based cameras would reduce the burden of the health systems in screening for sight-threatening retinopathy. Use of artificial intelligence to analyze retinal images is a significant development and it fits in well with the current trend of using telemedicine to reach the remote underserved parts of the country especially the rural areas where specialized healthcare is often non-existent.”
Dr. R. Rajalakshmi, Head-Medical Retina, Dr. Mohan’s Diabetes Specialities Centre and MDRF said, “Regular retinal screening for all people with diabetes is still an unmet need in most countries especially in poor developing countries. Automated artificial intelligence software along with smartphone-based retinal imaging can be a promising initial tool for mass retinal screening.” She added that smartphone retinal color photography combined with an automated detection system can ideally result in models with potential for cost-effective routine clinical use by the primary care physicians.
Dr. Anand Sivaraman, CEO of Remidio Innovative Solutions Pvt. Ltd., said, “The simplicity achieved by combining smartphones with our patented optics has resulted in Remidio Fundus On Phone to be priced at 1/5th to 1/10th of any traditional desktop retinal imaging system, delivering high quality relevant images repeatedly with high sensitivity and specificity exceeding 92% and 98% when clinically validated. The use of artificial intelligence like EyeArt™ in screening the images from the Remidio Fundus on Phone device, now enables large scale public health screening for eye health among the 400 million affected by Diabetes, globally.”
ABOUT EYENUK, INC.
Eyenuk, Inc., headquartered in Los Angeles, California, is an AI diagnostic company focused on quickly and accurately identifying patients suffering from potentially blinding eye diseases and chronic diseases at the point of care. Using computer vision and machine learning expertise, the company is developing a portfolio of products based on its proprietary retinal image analysis technology combined with deep learning to identify and track the progression of diseases including diabetic retinopathy, glaucoma, age-related macular degeneration, risk of stroke, cardiovascular risk, and Alzheimer’s disease. EyeArt™ development was partially supported by prestigious National Eye Institute (NEI/NIH) grants (EB013585, EY026864, EY027241). EyeArt™ has received CE Marking and Health Canada approval, and is commercially available in the European Union and in Canada. In the United States, EyeArt™ is limited by federal law to investigational use only and is not available for sale. For more information, visit www.eyenuk.com.
ABOUT MADRAS DIABETES RESEARCH FOUNDATION:
Madras Diabetes Research Foundation (MDRF), a unique 100% nonprofit research centre exclusively devoted for advanced research on diabetes and its complications, was established in 1996. Madras Diabetes Research Foundation is recognized by the Indian Council of Medical Research (ICMR) as “ICMR Centre for Advanced Research on Diabetes.”
ABOUT REMIDIO INNOVATIVE SOLUTIONS PVT LTD:
Remidio is an innovative medical device company that seeks to create Healthcare Access by combining simplicity of product design with cutting edge technology and sustainable business model innovations. Remidio uses principles of Design Thinking and involves key stakeholders during the product development process – clinicians, patients, and health workers, with a view to designing product solutions that are simple to use, clinically relevant, reliable and scalable. Remidio’s CE marked and FDA 510k registered retinal imaging devices have helped screen and impact more than 7.5 million patients in 15 countries globally, as a result of increased access provided by the ease of use and affordability of Remidio’s patented optics on the smartphone platform.
Kevin Skol, +1 (707) 702-3585
Dr. V. Mohan, +91 44- 4396 8888
Dr. R. Rajalakshmi, +91 44- 4396 8888
Dr. Anand Sivaraman, +91 9845155475
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
NBC Universal, Havas Group and Endemol Shine Discuss a Future with AI, Blockchain and VR at IBC201825.5.2018 21:20 | Tiedote
As is fitting for the home of technical invention and innovation, IBC2018 will present a broad range of ambitious and timely elements to engage, inform and inspire content creators and owners from around the world that will visit the RAI, Amsterdam from 13-18 September 2018. The must-attend event includes fresh inspiring conference themes that will focus on innovative new platforms, audience engagement and interaction/immersion, as well as a wide-ranging exhibition that will encompass all the latest technologies from AI and VR to advanced cloud-based workflows. Registration for IBC2018 is now open at: https://ibc.itnint.com/IBC18/Online/RegLogin.aspx “The media landscape is evolving at an unprecedented rate, with new platforms, technologies and even new realities at our disposal that offer greater opportunities for content innovation and audience engagement,” said Michael Crimp, CEO, IBC. “IBC is preparing an outstanding programme of conference sessions, forums and exhibition features
Pavilion of France at the 16th International Architecture Exhibition – La Biennale di Venezia25.5.2018 12:26 | Tiedote
The concept for Infinite Places , developed by the Encore Heureux team, led by the architects Nicola Delon, Julien Choppin, and Sébastien Eymard, presents places produced by new and inventive processes that generate architectural processes of value. This exhibition project, which considers the territory as a whole, highlights initiatives on the part of civil society and communities that embody a certain free spirit of experimentation and the possibilities opened up by architecture. These projects are expressions of programmatic freedom and generosity, and they live up to the theme of Freespace adopted by the two commissioners of the 16th International Architecture Exhibition – La Biennale di Venezia, the Irish architects Yvonne Farrell and Shelly McNamara. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180525005191/en/ French Pavilion Venice Architectural Biennale, copyright S. Scher Statement of the curators « Through the I
SIA Acquires Card Processing Businesses in Central and Southeastern Europe from First Data25.5.2018 11:30 | Tiedote
SIA, a European high-tech leader in payment infrastructure and services, and First Data Corporation (NYSE: FDC), a global leader in commerce-enabling technology, have signed an agreement for SIA to acquire First Data’s card processing businesses in parts of Central and Southeastern Europe for €375 million. In 2017, these businesses generated a combined revenue of approximately €100 million for First Data. This acquisition by SIA provides card processing, card production, call center and back-office services, including 13.3 million payment cards, 1.4 billion transactions, in addition to the management of POS terminals and ATMs. These businesses are primarily located in 7 countries: Greece, Croatia, Czech Republic, Hungary, Romania, Serbia and Slovakia. As a result of the transaction, SIA will become a leading player in processing and services in the region. The agreement includes the transfer of about 1,400 First Data employees into SIA. “This acquisition is in line with our strategy to
BRIC HOLDING Offers Aimedis – ICO: Germany’s Leading eHealth Platform Goes Public25.5.2018 09:00 | Tiedote
Since Wednesday, May 16, investors finally have a chance to claim their share of a unique success story, the international market roll-out of Aimedis, by purchasing AIM tokens: AIM tokens are now available with a 20% presale bonus PLUS a 5% early bird-premium only at the Czech investment house BRIC INVEST https://www.bric-holding.com/home_en.html! Aimedis aims to shape the future of healthcare by providing an advanced and fully operational platform, secured by blockchain and supported by AI, that enables patients to take control, secure the exchange of their medical data, access the best healthcare providers, get advice, prescriptions, personal health upgrades and to become part of the health revolution. And we are not talking about the future: The revolutionary Aimedis platform is already deployed as a live working system and is already in use in major hospital groups in Germany! By issuing 300 million AIM tokens at a nominal value of 0,12 USD each, the Aimedis consortium will raise c
Westinghouse Accident Tolerant Fuel Development Moves Forward with Cooperation Agreement with ENUSA25.5.2018 09:00 | Tiedote
Westinghouse Electric Company today announced that it will collaborate in the development of its EnCore® Fuel, the revolutionary accident-tolerant fuel (ATF) design, with ENUSA Industrias Avanzadas (ENUSA) through a Frame Cooperation Agreement (FCA). “This agreement serves to strengthen the technical and commercial relations between ENUSA and Westinghouse as we work to develop leading nuclear fuel technology,” said Torbjörn Norén, European Fuel Group and EMEA Fuel Delivery Director at Westinghouse. “Westinghouse’s work with ENUSA in the Spanish and European Fuel Group markets will help to facilitate agreements with customers to launch EnCore Fuel demonstration programs in their plants.” Under the terms of the agreement, the newly signed FCA establishes the framework that will regulate the different Joint Development Programs (JDPs) to be launched between both companies. The first JDP will evaluate the application of the segmented rod concept and develop models of ATF / EnCore fuel beha
Alps Electric to Acquire Greina Technologies, Inc. as Part of Sensor Business Strengthening25.5.2018 05:33 | Tiedote
Alps Electric Co., Ltd. (TOKYO: 6770; President: Toshihiro Kuriyama; Head Office: Tokyo) today announces that on May 14, 2018 the company signed a share purchase agreement with Greina Technologies, Inc. (Salt Lake City, Utah, U.S.A.; President/CTO: Daniel J. Lee) whereby Alps Electric will acquire Greina Technologies, making it a wholly owned subsidiary. Alps Electric signed a share purchase agreement with Greina Technologies on May 14, 2018. Through the agreement, Alps Electric aims to add even greater value to its sensing solutions for the automotive market, as well as the consumer electronics and mobile market, by combining high-accuracy positioning technology based on original algorithms developed by Greina Technologies with Alps Electric’s compact, high-performance wireless communication module technology. An engineering firm specializing in positioning systems, Greina Technologies was established in Salt Lake City, Utah, in September 2012. Engaging in such activities as design an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme